(Q41869801)

13 October 2017

Effect of fenofibrate in combination with urate lowering agents in patients with gout (English)

1 reference

13 October 2017

You-Hyun Lee

1

1 reference

13 October 2017

Chan-Hee Lee

series ordinal

2

1 reference

13 October 2017

Jisoo Lee

series ordinal

3

1 reference

13 October 2017

language of work or name

1 reference

1 June 2006

1 reference

The Korean journal of internal medicine

13 October 2017

1 reference

13 October 2017

21

1 reference

13 October 2017

2

1 reference

13 October 2017

89-93

1 reference

Creative Commons Attribution-NonCommercial 3.0 Unported

13 October 2017

start time

1 January 2006

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Fenofibrate for patients with asymptomatic primary biliary cirrhosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3890742

Prevalence of rheumatic symptoms, rheumatoid arthritis, ankylosing spondylitis, and gout in Shanghai, China: a COPCORD study

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3890742

Effects of combination treatment using anti-hyperuricaemic agents with fenofibrate and/or losartan on uric acid metabolism

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3890742

Pathogenesis of hyperuricemia: recent advances

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3890742

Statin + fibrate combination therapy fluvastatin with bezafibrate or ciprofibrate in high risk patients with vascular disease

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3890742

Micronised fenofibrate: a review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3890742

Induction of cyclooxygenase-2 expression by peroxisome proliferators and non-tetradecanoylphorbol 12,13-myristate-type tumor promoters in immortalized mouse liver cells

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3890742

The effect of bezafibrate treatment on serum alkaline phosphatase isoenzyme activities

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3890742

Impaired lipoprotein metabolism in patients with primary gout--influence of alcohol intake and body weight

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3890742

Apolipoprotein E phenotypes in patients with gout: relation with hypertriglyceridaemia

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3890742

Effect of fenofibrate on uric acid metabolism in Japanese hyperlipidemic patients.

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3890742

Fenofibrate enhances urate reduction in men treated with allopurinol for hyperuricaemia and gout

18 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3890742

Epidemiology of gout: is the incidence rising?

18 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3890742

Effects of various fibrates on serum alkaline phosphatase activity.

18 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3890742

Hyperuricemia and gout in Taiwan: results from the Nutritional and Health Survey in Taiwan (1993-96).

18 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3890742

Regulation of renal urate excretion: a critical review.

18 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3890742

Clustering of dyslipidemia, hyperuricemia, diabetes, and hypertension and its association with fasting insulin and central and overall obesity in a general population. Atherosclerosis Risk in Communities Study Investigators

18 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3890742

Uricosuric effect of fenofibrate in healthy volunteers

18 August 2018

1 reference

12 December 2020

Hypertriglyceridemia and hyperuricemia: effects of two fibric acid derivatives (bezafibrate and fenofibrate) in a double-blind, placebo-controlled trial

1 reference

12 December 2020

Hyperuricemia-hyperlipemia association in the absence of obesity and alcohol abuse

1 reference

12 December 2020

Dietary alterations in plasma very low density lipoprotein levels modify renal excretion of urates in hyperuricemic-hypertriglyceridemic patients

1 reference

12 December 2020

Fenofibrate decreases plasma fibrinogen, improves lipid profile, and reduces uricemia

1 reference

12 December 2020

10.3904/KJIM.2006.21.2.89

Identifiers

DOI

1 reference

13 October 2017

1 reference

13 October 2017

PubMed publication ID

16913436

1 reference